DECISION: Progression-free Survival
(by Independent Central Review)
Brose M, et al. Lancet 2014
n
Median PFS,
days (months)
Sorafenib 207
329 (
10.8
)
Placebo
210
175 (
5.8
)
PFS Probability (%)
Days From Randomization
0
100 200 300 400 500 600 700 800
0
10
20
40
60
80
100
30
50
70
90
HR, 0.59; 95% CI, 0.45-0.76;
P
<0.0001
